Surrozen (NASDAQ:SRZN) Major Shareholder Tcg Crossover Gp Ii, Llc Buys 15,223 Shares

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc purchased 15,223 shares of the company’s stock in a transaction on Monday, March 23rd. The shares were purchased at an average price of $24.90 per share, for a total transaction of $379,052.70. Following the purchase, the insider owned 683,225 shares in the company, valued at approximately $17,012,302.50. The trade was a 2.28% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Tuesday, March 24th, Tcg Crossover Gp Ii, Llc acquired 106,658 shares of Surrozen stock. The stock was purchased at an average price of $24.69 per share, with a total value of $2,633,386.02.
• On Monday, March 16th, Tcg Crossover Gp Ii, Llc acquired 1,190 shares of Surrozen stock. The stock was purchased at an average price of $24.99 per share, with a total value of $29,738.10.
• On Friday, March 13th, Tcg Crossover Gp Ii, Llc bought 35,433 shares of Surrozen stock. The shares were purchased at an average cost of $24.88 per share, with a total value of $881,573.04.
• On Thursday, March 12th, Tcg Crossover Gp Ii, Llc bought 12,374 shares of Surrozen stock. The stock was purchased at an average price of $24.99 per share, for a total transaction of $309,226.26.
• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc purchased 1,093 shares of Surrozen stock. The stock was acquired at an average price of $23.86 per share, for a total transaction of $26,078.98.
• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc purchased 17,763 shares of Surrozen stock. The shares were acquired at an average cost of $23.57 per share, with a total value of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc purchased 4,355 shares of Surrozen stock. The shares were acquired at an average cost of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc acquired 731 shares of Surrozen stock. The shares were acquired at an average price of $21.38 per share, with a total value of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc acquired 4,271 shares of Surrozen stock. The stock was acquired at an average cost of $21.39 per share, for a total transaction of $91,356.69.

Surrozen Price Performance

NASDAQ:SRZN opened at $26.14 on Thursday. The firm has a market capitalization of $224.02 million, a P/E ratio of -0.78 and a beta of 0.53. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $29.59. The company’s fifty day moving average price is $24.34 and its 200-day moving average price is $18.81.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Monday, March 23rd. The company reported ($7.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.29) by ($6.30). The business had revenue of $0.53 million for the quarter, compared to analysts’ expectations of $0.66 million. Surrozen had a negative return on equity of 1,240.42% and a negative net margin of 7,476.67%. Equities analysts anticipate that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Analyst Ratings Changes

SRZN has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $40.00 price objective on shares of Surrozen in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price (up from $32.00) on shares of Surrozen in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. Finally, Wall Street Zen raised Surrozen to a “sell” rating in a report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $38.00.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its position in shares of Surrozen by 50.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares during the period. Persistent Asset Partners Ltd acquired a new stake in shares of Surrozen during the 4th quarter valued at about $99,000. Marshall Wace LLP purchased a new position in shares of Surrozen in the 4th quarter valued at about $247,000. Ieq Capital LLC purchased a new position in shares of Surrozen in the 4th quarter valued at about $304,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Surrozen in the 4th quarter valued at about $310,000. Institutional investors and hedge funds own 66.57% of the company’s stock.

Key Stories Impacting Surrozen

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Major shareholder TCG Crossover GP II purchased 106,658 shares on March 24 at an average $24.69, increasing its stake ~16.9% to 736,554 shares — a strong insider-buy signal that can support the stock. SEC Filing
• Positive Sentiment: TCG Crossover also bought 15,223 shares on March 23 at ~$24.90, a smaller follow-on purchase that further signals insider confidence. SEC Filing
• Positive Sentiment: Cantor Fitzgerald reaffirmed an “overweight” rating with a $40 price target — a materially higher valuation that may attract buyers. Benzinga
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and raised its target to $36. Its analyst also issued a FY2030 EPS forecast (-$3.54), notably less negative than the broader consensus, signaling a more optimistic long-term view. TickerReport
• Neutral Sentiment: Short-interest reports for March show zero shorted shares and a 0.0 days-to-cover metric, but the entries include NaN and look inconsistent — treat this as unreliable data rather than a clear market signal.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.